Search

Your search keyword '"Gainor, J."' showing total 354 results

Search Constraints

Start Over You searched for: Author "Gainor, J." Remove constraint Author: "Gainor, J."
354 results on '"Gainor, J."'

Search Results

52. 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy

53. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

54. 1O Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial)

55. Monstrous Regiment (1975-1993)

56. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

58. 1170P Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)

59. 984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)

60. MA15.09 LCMC3: Long-Term Disease-Free and Overall Survival and their Association with ctDNA after Neoadjuvant Atezolizumab for NSCLC

65. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

66. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

67. Quantitative Evaluation of Normal Lung Density Changes in Non-Small Cell Lung Cancer Patients Treated With Radiotherapy and PD-1 Immune Checkpoint Inhibitors

69. SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer

70. Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)

71. Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)

72. OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

73. P75.03 KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC

74. P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status

76. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

78. Activité intracrânienne du selpercatinib (LOXO-292) chez les patients atteints d’un cancer bronchique non à petites cellules (CBNPC) exprimant le gène de fusion RET dans le cadre de l’essai LIBRETTO-001

84. Screening of ‘unbiased’ immobilized peptide library vs. proteases: An approach for rapid determination of substrate specificity and selectivity

85. Immobilized peptide arrays: A new technology for the characterization of protease function

86. Relationship between structure and bio-availability in a series of hydroxamate based metalloprotease inhibitors

88. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC

92. The Feminist Possibilities of Dramatic Realism

94. MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement

99. Competitive ballroom dancing is back!

100. P3.07-012 Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases

Catalog

Books, media, physical & digital resources